

CONCLUSION

Mutations in *BRCA1* and, more commonly, *BRCA2* mutations are associated with increased risk of MBC. Given the paucity of data on MBC, and germline mutations in *BRCA1/2*, each case report shall build into existing literature, and help guide treatment regimens.

REFERENCES

1. Fiala L., Coufal O., Fait V., Foretova L. Male breast cancer: our experience. *Rozhl. Chir.* 2010;89(10):612–618.
2. A. Sanguinetti A. Polistena R. Lucchini M. Monacelli S. Galasse S. Avenia R. Triola W. Bugiantell R. Cirocchi F. Rondelli and N. Aveniab. Male breast cancer, clinical presentation, diagnosis and treatment: Twenty years of experience in our Breast Unit. *Int J Surg Case Rep.* 2016; 20(Suppl): 8–11
3. Easton, D. F., Steele, L., Fields, P., Ormiston, W., Averill, D., Daly, P. A., McManus, R., Neuhausen, S. L., Ford, D., Wooster, R., Cannon Albright, L. A., Stratton, M. R., Goldgar, D. E. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12. *Am. J. Hum. Genet.* 61: 120-128, 1997.
4. Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., Urban, N., Taniguchi, T. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. *Nature* 451: 1116-1120, 2008.
5. Maxwell KN, Wubbenhorst B, Wenz BM, De Sloover D, Pluta J, Emery L, Barrett A, Kraya AA, Anastopoulos IN, Yu S, Jiang Y, Chen H, Zhang NR, Hackman N, Andrea K, Daber R, Morrissette JJD, Mitra N, Feldman M, Domchek SM, Nathanson KL. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. *Nat Commun.* 2017 Aug 22;8(1):319.
6. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 1.2018 - March 20, 2018. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf